TRAP
MCID: TRD008
MIFTS: 34

Triiodothyronine Receptor Auxiliary Protein (TRAP)

Aliases & Classifications for Triiodothyronine Receptor Auxiliary Protein

MalaCards integrated aliases for Triiodothyronine Receptor Auxiliary Protein:

Name: Triiodothyronine Receptor Auxiliary Protein 56
Trap 56

External Ids:

OMIM 56 190445

Summaries for Triiodothyronine Receptor Auxiliary Protein

MalaCards based summary : Triiodothyronine Receptor Auxiliary Protein, also known as trap, is related to periodic fever, familial, autosomal dominant and thyroid dyshormonogenesis 1. An important gene associated with Triiodothyronine Receptor Auxiliary Protein is TRAP (Triiodothyronine Receptor Auxiliary Protein). The drugs Certoparin and Linagliptin have been mentioned in the context of this disorder. Affiliated tissues include bone, neutrophil and eye.

More information from OMIM: 190445

Related Diseases for Triiodothyronine Receptor Auxiliary Protein

Diseases related to Triiodothyronine Receptor Auxiliary Protein via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1207)
# Related Disease Score Top Affiliating Genes
1 periodic fever, familial, autosomal dominant 12.4
2 thyroid dyshormonogenesis 1 11.7
3 neural tube defects 11.4
4 coronary artery dissection, spontaneous 11.4
5 hidradenitis suppurativa 11.4
6 nerve compression syndrome 11.4
7 gas gangrene 11.4
8 dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edema 11.3
9 spondyloenchondrodysplasia with immune dysregulation 11.3
10 epidermoid brain cyst 11.3
11 duodenal atresia 11.1
12 hepatic fibrosis, severe due to schistosoma mansoni infection 11.1
13 dehydrated hereditary stomatocytosis 2 11.1
14 tonsillitis 11.1
15 fox-fordyce disease 11.1
16 miliaria 11.1
17 paraphimosis 11.1
18 priapism 11.1
19 catamenial pneumothorax 11.1
20 autoimmune disease 10.4
21 aneurysm 10.4
22 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
23 vasculitis 10.4
24 systemic lupus erythematosus 10.3
25 lung disease 10.3
26 west nile virus 10.3
27 hair whorl 10.3
28 lupus erythematosus 10.3
29 cystic fibrosis 10.2
30 malaria 10.2
31 helix syndrome 10.2
32 hydrocephalus 10.2
33 pulmonary disease, chronic obstructive 10.2
34 amyloidosis 10.2
35 kala-azar 1 10.2
36 leishmaniasis 10.2
37 pulmonary embolism 10.2
38 anca-associated vasculitis 10.2
39 thrombosis 10.2
40 patent foramen ovale 10.2
41 thrombophilia due to thrombin defect 10.2
42 chikungunya 10.2
43 encephalitis 10.2
44 rapidly involuting congenital hemangioma 10.2
45 pica disease 10.2
46 vaccinia 10.1
47 exanthem 10.1
48 macular degeneration, age-related, 1 10.1
49 bone resorption disease 10.1
50 kidney disease 10.1

Graphical network of the top 20 diseases related to Triiodothyronine Receptor Auxiliary Protein:



Diseases related to Triiodothyronine Receptor Auxiliary Protein

Symptoms & Phenotypes for Triiodothyronine Receptor Auxiliary Protein

Clinical features from OMIM:

190445

Drugs & Therapeutics for Triiodothyronine Receptor Auxiliary Protein

Drugs for Triiodothyronine Receptor Auxiliary Protein (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 285)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Certoparin Approved, Investigational Phase 4
2
Linagliptin Approved Phase 4 668270-12-0 10096344
3
Verteporfin Approved, Investigational Phase 4 129497-78-5
4
Sodium citrate Approved, Investigational Phase 4 68-04-2
5
Ranibizumab Approved Phase 4 347396-82-1 459903
6
Thrombin Approved, Investigational Phase 4
7
Vorapaxar Approved Phase 4 618385-01-6
8
Histamine Approved, Investigational Phase 4 51-45-6 774
9
Sucralfate Approved Phase 4 54182-58-0
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
13
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
14
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
15
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
16 Incretins Phase 4
17 Dipeptidyl-Peptidase IV Inhibitors Phase 4
18 Photosensitizing Agents Phase 4
19 Citrate Phase 4
20 Gastrointestinal Agents Phase 4
21 Anti-Ulcer Agents Phase 4
22 Bismuth tripotassium dicitrate Phase 4
23 Histamine H2 Antagonists Phase 4
24 Histamine Antagonists Phase 4
25
Histamine Phosphate Phase 4 51-74-1 65513
26 Ranitidine bismuth citrate Phase 4
27
Bismuth Phase 4 7440-69-9 16682734 105143
28 Antacids Phase 4
29 Vaccines Phase 4
30 Pharmaceutical Solutions Phase 4
31 Calcium, Dietary Phase 4
32 Hormones Phase 4
33 Trace Elements Phase 4
34 Vitamins Phase 4
35 Micronutrients Phase 4
36 Nutrients Phase 4
37 Calciferol Phase 4
38 Vitamin D2 Phase 4
39 Ergocalciferols Phase 4
40 Anesthetics Phase 4
41
tannic acid Approved Phase 3 1401-55-4
42
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
43
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
44
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
45
Rilonacept Approved, Investigational Phase 3 501081-76-1 104924
46
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
47
Warfarin Approved Phase 2, Phase 3 81-81-2 6691 54678486
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
49
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
50 Grape Approved Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 312)
# Name Status NCT ID Phase Drugs
1 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
2 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
3 An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
4 AflibercepT for Subjects Who Are Incomplete Responders to mUltiple Intravitreal Injections of Ranibizumab, Anti-VegF (The TURF Study) Completed NCT01543568 Phase 4 aflibercept 2.0 mg
5 Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy Completed NCT02072408 Phase 4 aflibercept
6 Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
7 A Randomized, Double-masked, Sham-controlled Phase 3b/4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy as Indicated in Subjects With Polypoidal Choroidal Vasculopathy Completed NCT02120950 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
8 An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
9 Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES) Completed NCT02581891 Phase 4 Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321);Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
10 A Randomized, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Repeated Doses of Intravitreal Aflibercept With Variable Treatment Intervals in Japanese Subjects With Neovascular Age-related Macular Degeneration Completed NCT02305238 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
11 NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
12 Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) Completed NCT01663103 Phase 4 Rilonacept;Placebo
13 Efficacy of Intravitreal Aflibercept Monotherapy for Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial Completed NCT03169660 Phase 4 Vascular endothelial growth factor trap-eye
14 Vorapaxar in the Human Endotoxemia Model A Randomized, Double‐Blind, Crossover Study Completed NCT02875028 Phase 4 Vorapaxar;Placebo
15 A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT02800642 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
16 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
17 A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study Completed NCT00702871 Phase 4 Ranitidine;Sucralfate
18 Grass Pollen Subcutaneous Immunotherapy: a Double-blind, Placebo-controlled Study in Elderly Patients With an Allergy to Grass Pollen Completed NCT02440243 Phase 4 Purethal;Purethal -placebo
19 Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy Recruiting NCT02621645 Phase 4
20 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples Recruiting NCT01824537 Phase 4
21 Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients Active, not recruiting NCT02999204 Phase 4 Vitamin D3
22 The Effect of the Tunneling Technique With Subepithelial Connective Tissue Graft Versus Tunneling Technique With Deepithelialized Free Gingival Graft on the Papillary Height in the Treatment of RT2 Recession Defect: a Randomized Clinical Trial. Not yet recruiting NCT04104087 Phase 4
23 Estimation of MMP-8 Levels in GCF and Serum and Its Correlation With Wound Healing and Clinical Outcomes After Coronally Advanced Flap and Subepithelial Connective Tissue Graft for Root Coverage in Recession Defects: A CLINICO-BIOCHEMICAL STUDY Suspended NCT02863744 Phase 4
24 Phase III Study of Additional Minocycline Pleurodesis After Video-Assisted Thoracoscopic Surgery for Primary Spontaneous Pneumothorax Unknown status NCT00154895 Phase 3 intrapleural minocycline instillation
25 Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial Unknown status NCT00720967 Phase 3
26 An Open-label Phase III Study Evaluating the Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap-Eye in Japanese Subjects With Diabetic Macular Edema Completed NCT01512966 Phase 3
27 A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema Completed NCT01331681 Phase 3
28 A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema Completed NCT01783886 Phase 3
29 A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration Completed NCT01482910 Phase 3 Visudyne
30 A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
31 A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT00943072 Phase 3 Sham
32 A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia Completed NCT01249664 Phase 3
33 A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT01521559 Phase 3 Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
34 A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema Completed NCT01363440 Phase 3 Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
35 An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of Three Different Treatment Regimens of 2 mg Aflibercept Administered by Intravitreal Injections to Subjects With Diabetic Macular Edema (DME) Completed NCT02818998 Phase 3 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
36 A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration Completed NCT00509795 Phase 3
37 An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration Completed NCT00964795 Phase 3 Intravitreal Aflibercept Injection 2mg
38 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed NCT00327444 Phase 2, Phase 3 aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Placebo;aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
39 WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF) Completed NCT00129545 Phase 2, Phase 3 Warfarin
40 Three-month Outcome of Ziv-aflibercept for Diabetic Macular Edema Completed NCT02772497 Phase 2, Phase 3 Ziv aflibercept
41 A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD) Completed NCT00637377 Phase 3 Ranibizumab
42 Correction of Vitamin D Deficiency in Critically Ill Patients: a Randomized, Double-blind, Placebo-controlled Trial ("VITDAL@ICU") Completed NCT01130181 Phase 3 Cholecalciferol;Placebo
43 A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-Line Docetaxel After Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed NCT00532155 Phase 3 Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Placebo;Docetaxel (Taxotere®);Dexamethasone (pre- and post-medication for docetaxel)
44 Randomized, Cross-Over, Double Blind, Placebo-Controlled Study of Grape Seed Extract in Treating Patients With Mild Hyperlipidemia Completed NCT00713167 Phase 2, Phase 3 Grape Seed Extract (Vitagrape);Placebo of Grape Seed Extract
45 Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet activation-a Single Center Pilot Study Completed NCT03455218 Phase 2, Phase 3 Nitric Oxide;Placebo
46 A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxaliplatin Based Regimen Completed NCT00561470 Phase 3 Placebo;Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin);FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
47 Trial to Reduce Alloimmunization to Platelets (TRAP) Completed NCT00000589 Phase 3
48 IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs Completed NCT00288704 Phase 3 rilonacept 160 mg;Placebo;rilonacept 160 mg
49 Sequential Preoperative Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization to Induce Further Liver Regeneration in Patients With Hepatobiliary Malignancy Completed NCT00698880 Phase 2, Phase 3
50 Diagnosis of Ventilator- Associated Pneumonia in Children: A Comparative Study of Bronchoscopic and Non-Bronchoscopic Methods Completed NCT00495963 Phase 3

Search NIH Clinical Center for Triiodothyronine Receptor Auxiliary Protein

Genetic Tests for Triiodothyronine Receptor Auxiliary Protein

Anatomical Context for Triiodothyronine Receptor Auxiliary Protein

MalaCards organs/tissues related to Triiodothyronine Receptor Auxiliary Protein:

40
Bone, Neutrophil, Eye, Endothelial, Lung, Testes, Liver

Publications for Triiodothyronine Receptor Auxiliary Protein

Articles related to Triiodothyronine Receptor Auxiliary Protein:

(show top 50) (show all 30002)
# Title Authors PMID Year
1
3,5,3'-triiodothyronine receptor auxiliary protein (TRAP) enhances receptor binding by interactions within the thyroid hormone response element. 61 56
1708100 1991
2
Implementation of Synaptic Device Using Various High-k Gate Dielectric Stacks. 61
31968460 2020
3
Charge Transport Properties of Hybrid Nanocomposites Based on Colloidal PbSe Quantum Dots in Poly(2-methoxy,5-(2'-ethylhexyloxy)-P-Phenylenevinylene (MEH-PPV) Matrix. 61
31748080 2020
4
Formation of a creatinine thermal degradation product and its role and participation in the radical pathway of forming the pyridine ring of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). 61
31901823 2020
5
Interplay between neutrophils and trophoblast cells conditions trophoblast function and triggers vascular transformation signals. 61
31559642 2020
6
Targeted metabolomics: Liquid chromatography coupled to mass spectrometry method development and validation for the identification and quantitation of modified nucleosides as putative cancer biomarkers. 61
31987192 2020
7
The fly factor phenomenon is mediated by interkingdom signaling between bacterial symbionts and their blow fly hosts. 61
30047567 2020
8
Data on winged insect dynamics in melon crops in southeastern France. 61
32016141 2020
9
Database of free solution mobilities for 276 metabolites. 61
31892063 2020
10
Transcriptional landscape of pathogen-responsive lncRNAs in rice unveils the role of ALEX1 in jasmonate pathway and disease resistance. 61
31419052 2020
11
A simple equipment and colorimetric method for determination of chloroform in water. 61
31987142 2020
12
Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss. 61
31846839 2020
13
Photo-Induced Charge Transfer on Pt/Bi₂WO6 Composite Photocatalysts. 61
31492350 2020
14
On-site testing of multiple drugs of abuse in urine by a miniature dual-LIT mass spectrometer. 61
32029121 2020
15
Sink trap: duckweed and dye attractant reduce mosquito populations. 61
31638276 2020
16
Inhibitory effects of resveratrol on orthodontic tooth movement and associated root resorption in rats. 61
31887570 2020
17
Lithium chloride improves bone filling around implants placed in estrogen-deficient rats. 61
31896027 2020
18
Comparison of RNA isolation procedures for analysis of adult murine brain and spinal cord astrocytes. 61
31821821 2020
19
Plectin stabilizes microtubules during osteoclastic bone resorption by acting as a scaffold for Src and Pyk2. 61
31866495 2020
20
Trap Height Affects Catches of Bark and Woodboring Beetles (Coleoptera: Curculionidae, Cerambycidae) in Baited Multiple-Funnel Traps in Southeastern United States. 61
31617908 2020
21
Catch me if you can: the influence of refuge / trap design, previous feeding experience, and semiochemical lures on vine weevil (Coleoptera: Curculionidae) monitoring success. 61
31282078 2020
22
NETosis in cancer: a critical analysis of the impact of cancer on neutrophil extracellular trap (NET) release in lung cancer patients vs. mice. 61
31982939 2020
23
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. 61
31809243 2020
24
A Novel Sandwich ELISA for Tartrate-Resistant Acid Phosphatase 5a and 5b Protein Reveals that Both Isoforms are Secreted by Differentiating Osteoclasts and Correlate to the Type I Collagen Degradation Marker CTX-I In Vivo and In Vitro. 61
31654098 2020
25
Characterization of Polyethers Using Tandem Mass Spectrometry with Hydrogen Abstraction Dissociation and Thermal Activation. 61
31951697 2020
26
Osteoclasts Derive Predominantly from Bone Marrow-Resident CX3CR1+ Precursor Cells in Homeostasis, whereas Circulating CX3CR1+ Cells Contribute to Osteoclast Development during Fracture Repair. 61
31915261 2020
27
Characterization of the metabolites of H3B-6545 in vitro and in vivo by using ultra-high performance liquid chromatography combined with electrospray ionization linear ion trap-orbitrap tandem mass spectrometry. 61
31725913 2020
28
Inhibitory effects of dabigatran etexilate, a direct thrombin inhibitor, on osteoclasts and osteoblasts. 61
31883999 2020
29
Microchamber arrays made of biodegradable polymers for enzymatic release of small hydrophilic cargos. 61
32039413 2020
30
A20 inhibits osteoclastogenesis via TRAF6-dependent autophagy in human periodontal ligament cells under hypoxia. 61
32027437 2020
31
Plastic debris accumulation in the seabed derived from coastal fish farming. 61
31753624 2020
32
Functional Dynamics of Neutrophils After Ischemic Stroke. 61
30847778 2020
33
Synergistic Effects of Polymer Donor Backbone Fluorination and Nitrogenation Translate into Efficient Non-Fullerene Bulk-Heterojunction Polymer Solar Cells. 61
32013390 2020
34
Soft-Matter Nanotubes: A Platform for Diverse Functions and Applications. 61
32013405 2020
35
New solutions to capture and enrich bacteria from complex samples. 61
32025887 2020
36
Revegetation and reproduction: do restoration plantings in agricultural landscapes support breeding populations of woodland birds? 61
32025896 2020
37
Effect of different inoculation strategies of selected yeast and LAB cultures on Conservolea and Kalamàta table olives considering phenol content, texture, and sensory attributes. 61
31523827 2020
38
Knockout of TLR4 promotes fracture healing by activating Wnt/β-catenin signaling pathway. 61
31796334 2020
39
Bovine serum albumin affects N-glycoforms of murine IgG monoclonal antibody purified from hybridoma supernatants. 61
31915902 2020
40
A comparison of cost and quality of three methods for estimating density for wild pig (Sus scrofa). 61
32029837 2020
41
A Focused Chiral Mutant Library of the Amyloid β 42 Central Electrostatic Cluster as a Tool To Stabilize Aggregation Intermediates. 61
31875394 2020
42
Surgical Stress Increases Circulating Low-Density Neutrophils Which May Promote Tumor Recurrence. 61
31561178 2020
43
Identification and quantification of Meiguihua oral solution using liquid chromatography combined with hybrid quadrupole-orbitrap and triple quadrupole mass spectrometers. 61
31991318 2020
44
Defect Passivation and Photoluminescence Enhancement of Monolayer MoS2 Crystals through Sodium Halides Assisted CVD Growth. 61
32009383 2020
45
Dimensionality-Controlled Surface Passivation for Enhancing Performance and Stability of Perovskite Solar Cells via Triethylenetetramine Vapor. 61
31918551 2020
46
Uniform Polypyrrole Layer-Coated Sulfur/Graphene Aerogel via the Vapor-Phase Deposition Technique as the Cathode Material for Li-S Batteries. 61
31922398 2020
47
Laboratory and field evaluation of an autoinoculation device as a tool to manage poultry red mite, Dermanyssus gallinae, infestations with Beauveria bassiana. 61
31950300 2020
48
Synergetic Covalent and Spatial Confinement of Sulfur Species by Phthalazinone-Containing Covalent Triazine Frameworks for Ultrahigh Performance of Li-S Batteries. 61
31985210 2020
49
Near Infrared-Triggered Liposome Cages for Rapid, Localized Small Molecule Delivery. 61
32015363 2020
50
Injection Molded Microfluidics for Establishing High-Density Single Cell Arrays in an Open Hydrogel Format. 61
31934750 2020

Variations for Triiodothyronine Receptor Auxiliary Protein

Expression for Triiodothyronine Receptor Auxiliary Protein

Search GEO for disease gene expression data for Triiodothyronine Receptor Auxiliary Protein.

Pathways for Triiodothyronine Receptor Auxiliary Protein

GO Terms for Triiodothyronine Receptor Auxiliary Protein

Sources for Triiodothyronine Receptor Auxiliary Protein

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....